Drug intelligence / Profile preview

epcoritamab + tafasitamab + lenalidomide

Development stage: Unknown
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous, Oral

Overview

This is an investigational combination therapy consisting of epcoritamab, tafasitamab, and lenalidomide. It is being evaluated in the Phase II REPIFIR trial, sponsored by the Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (GELTAMO), for the treatment of patients with first relapse or refractory large B-cell lymphoma (LBCL). Epcoritamab is a bispecific T-cell engager that targets CD3 on T cells and CD20 on B cells. Tafasitamab is a humanized monoclonal antibody targeting CD19. Lenalidomide is an immunomodulatory agent that enhances the activity of T cells and NK cells. The combination aims to provide a synergistic effect by targeting multiple B-cell antigens and enhancing immune-mediated cell death.

Other names: REPIFIR regimenepcoritamab + tafasitamab + lenalidomide-Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea-large B-cell lymphoma

Targets

CRBN (Cereblon)CD3 (T-cell surface glycoprotein CD3)CD20 (B-lymphocyte antigen CD20)CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on epcoritamab + tafasitamab + lenalidomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epcoritamab + tafasitamab + lenalidomide.

Explore the full profile